Medical Therapy for Advanced Forms of Thyroid Cancer
作者： Uma Rajhbeharrysingh , Matthew Taylor , Mira Milas
DOI: 10.1016/J.SUC.2014.03.003
关键词:
摘要: More options than ever before are currently available for medical therapy in patients who present with advanced thyroid cancer or develop surgically unresectable recurrences symptomatic progressive disease. The newer therapies have addressed the need to find effective beyond conventional treatment radioactive iodine, stimulating hormone suppression, and palliative cytotoxic chemotherapy cancer. Although tumor responses these vary by type of selected, they remain encouraging provide therapeutic selected while new drugs development.
elsevier.com
sci-hub.se 参考文章(81)
P. Grabowski, F. Briest, R.P. Baum, J.J. Zaknun, H.R. Kulkarni, M. Zeitz, D. Hörsch, Vandetanib therapy in medullary thyroid cancer. Drugs of Today. ,vol. 48, pp. 723- 733 ,(2012) , 10.1358/DOT.2012.48.11.1867323
M. M. Cooney, P. Savvides, S. Agarwala, D. Wang, S. Flick, S. Bergant, S. Bhakta, P. Lavertu, J. Ortiz, S. Remick, Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC) Journal of Clinical Oncology. ,vol. 24, pp. 5580- 5580 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5580
Richard O Wein, Randal S Weber, Anaplastic thyroid carcinoma: palliation or treatment? Current Opinion in Otolaryngology & Head and Neck Surgery. ,vol. 19, pp. 113- 118 ,(2011) , 10.1097/MOO.0B013E328343AF3D
S. I. Sherman, B. Jarzab, M. E. Cabanillas, L. F. Licitra, F. Pacini, R. Martins, B. Robinson, D. Ball, J. McCaffrey, M. H. Shah, D. Bodenner, R. Allison, K. Newbold, R. Elisei, J. P. O'Brien, M. Schlumberger, A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). Journal of Clinical Oncology. ,vol. 29, pp. 5503- 5503 ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.5503
J Pinto Couto, H Prazeres, P Castro, J Lima, V Máximo, P Soares, M Sobrinho-Simões, How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer Journal of Clinical Pathology. ,vol. 62, pp. 414- 421 ,(2009) , 10.1136/JCP.2008.055343
Kevin B. Kim, Maria E. Cabanillas, Alexander J. Lazar, Michelle D. Williams, Deborah L. Sanders, Joseph L. Ilagan, Keith Nolop, Richard J. Lee, Steven I. Sherman, Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation Thyroid. ,vol. 23, pp. 1277- 1283 ,(2013) , 10.1089/THY.2013.0057
Ya-Sian Chang, I-Ling Lin, Kun-Tu Yeh, Jan-Gowth Chang, Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension Clinical Biochemistry. ,vol. 46, pp. 1572- 1577 ,(2013) , 10.1016/J.CLINBIOCHEM.2013.06.005
Joana P. Couto, Ana Almeida, Laura Daly, Manuel Sobrinho-Simões, Jacqueline F. Bromberg, Paula Soares, AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines. PLOS ONE. ,vol. 7, ,(2012) , 10.1371/JOURNAL.PONE.0046869
Hari A. Deshpande, Sanziana Roman, Julie A. Sosa, New targeted therapies and other advances in the management of anaplastic thyroid cancer. Current Opinion in Oncology. ,vol. 25, pp. 44- 49 ,(2013) , 10.1097/CCO.0B013E32835A448C
Richard T. Kloos (Chair), Charis Eng, Douglas B. Evans, Gary L. Francis, Robert F. Gagel, Hossein Gharib, Jeffrey F. Moley, Furio Pacini, Matthew D. Ringel, Martin Schlumberger, Samuel A. Wells, Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. ,vol. 19, pp. 565- 612 ,(2009) , 10.1089/THY.2008.0403